PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 21, 2026ESMO OpenOpen Access

195eP Real-world safety of ALK inhibitors in non-small cell lung cancer patients: A FAERS disproportionality analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ADA.I. DraghiciDUD.A. UrdeaSES. Elrashidy

Discussion

Loading...

Member takes

Overview

This analysis uncovers resistance mechanisms in non-small cell lung cancer patients undergoing therapy, suggesting new targets for treatment.

Key Points

  • The study aims to analyze resistance mechanisms to targeted therapy in patients with advanced non-small cell lung cancer.
  • Performed massive-parallel sequencing on patient samples.
  • Analyzed 77 patients who progressed on targeted therapy.
  • Used TrueSight Oncology 500 sequencing.
  • Studied patients presented at the molecular tumorboard at the Center for Integrated Oncology Cologne.
  • Detected MET amplification as a common resistance mode in EGFR mutants.
  • Identified multiple resistance mutations in key cancer genes.
  • Discovered acquired mutations, including BRAF V600E in patients with EGFR mutations.
  • Found a new EML4::ALK fusion in a patient previously identified with EGFR exon 19 deletion.

Cite This Study

Draghici et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c673254https://doi.org/10.1016/j.esmoop.2026.106502
View Full Paper
Ask AI
Bookmark
Share